163 related articles for article (PubMed ID: 37111735)
1. Predicting Hydroxychloroquine Clearance in Healthy and Diseased Populations Using a Physiologically Based Pharmacokinetic Approach.
Alqahtani F; Asiri AM; Zamir A; Rasool MF; Alali AS; Alsanea S; Walbi IA
Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111735
[TBL] [Abstract][Full Text] [Related]
2. Development and Evaluation of Physiologically Based Pharmacokinetic Drug-Disease Models for Predicting Rifampicin Exposure in Tuberculosis and Cirrhosis Populations.
Rasool MF; Khalid S; Majeed A; Saeed H; Imran I; Mohany M; Al-Rejaie SS; Alqahtani F
Pharmaceutics; 2019 Nov; 11(11):. PubMed ID: 31694244
[TBL] [Abstract][Full Text] [Related]
3. Development and Evaluation of a Physiologically Based Pharmacokinetic Drug-Disease Model of Propranolol for Suggesting Model Informed Dosing in Liver Cirrhosis Patients.
Kalam MN; Rasool MF; Alqahtani F; Imran I; Rehman AU; Ahmed N
Drug Des Devel Ther; 2021; 15():1195-1211. PubMed ID: 33762817
[TBL] [Abstract][Full Text] [Related]
4. Physiologically Based Pharmacokinetic Model To Predict Metoprolol Disposition in Healthy and Disease Populations.
Zamir A; Rasool MF; Imran I; Saeed H; Khalid S; Majeed A; Rehman AU; Ahmad T; Alasmari F; Alqahtani F
ACS Omega; 2023 Aug; 8(32):29302-29313. PubMed ID: 37599939
[TBL] [Abstract][Full Text] [Related]
5. Investigating the Role of Altered Systemic Albumin Concentration on the Disposition of Theophylline in Adult and Pediatric Patients with Asthma by Using the Physiologically Based Pharmacokinetic Approach.
Rasool MF; Khalid R; Imran I; Majeed A; Saeed H; Alasmari F; Alanazi MM; Alqahtani F
Drug Metab Dispos; 2020 Jul; 48(7):570-579. PubMed ID: 32393652
[TBL] [Abstract][Full Text] [Related]
6. Development and Evaluation of a Physiologically Based Pharmacokinetic Model of Labetalol in Healthy and Diseased Populations.
Hafsa H; Zamir A; Rasool MF; Imran I; Saeed H; Ahmad T; Alsanea S; Alshamrani AA; Alruwaili AH; Alqahtani F
Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36365181
[TBL] [Abstract][Full Text] [Related]
7. Investigating clinical pharmacokinetics of brivaracetam by using a pharmacokinetic modeling approach.
Qayyum A; Zamir A; Rasool MF; Imran I; Ahmad T; Alqahtani F
Sci Rep; 2024 Jun; 14(1):13357. PubMed ID: 38858493
[TBL] [Abstract][Full Text] [Related]
8. A Comprehensive Physiologically Based Pharmacokinetic Model of Nadolol in Adults with Renal Disease and Pediatrics with Supraventricular Tachycardia.
Kalsoom S; Rasool MF; Imran I; Saeed H; Ahmad T; Alqahtani F
Pharmaceuticals (Basel); 2024 Feb; 17(2):. PubMed ID: 38399480
[TBL] [Abstract][Full Text] [Related]
9. A physiologically based pharmacokinetic model of cefepime to predict its pharmacokinetics in healthy, pediatric and disease populations.
Talha Zahid M; Zamir A; Majeed A; Imran I; Alsanea S; Ahmad T; Alqahtani F; Fawad Rasool M
Saudi Pharm J; 2023 Aug; 31(8):101675. PubMed ID: 37576858
[TBL] [Abstract][Full Text] [Related]
10. A Physiologically Based Pharmacokinetic Model for Predicting Diazepam Pharmacokinetics after Intravenous, Oral, Intranasal, and Rectal Applications.
Khalid S; Rasool MF; Imran I; Majeed A; Saeed H; Rehman AU; Ashraf W; Ahmad T; Bin Jardan YA; Alqahtani F
Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575556
[TBL] [Abstract][Full Text] [Related]
11. Physiologically-Based Pharmacokinetics Modeling for Hydroxychloroquine as a Treatment for Malaria and Optimized Dosing Regimens for Different Populations.
Zhai J; Ji B; Cai L; Liu S; Sun Y; Wang J
J Pers Med; 2022 May; 12(5):. PubMed ID: 35629219
[TBL] [Abstract][Full Text] [Related]
12. Optimizing the Clinical Use of Carvedilol in Liver Cirrhosis Using a Physiologically Based Pharmacokinetic Modeling Approach.
Rasool MF; Khalil F; Läer S
Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):383-396. PubMed ID: 27313074
[TBL] [Abstract][Full Text] [Related]
13. Development and evaluation of physiologically based pharmacokinetic drug-disease models for predicting captopril pharmacokinetics in chronic diseases.
Rasool MF; Ali S; Khalid S; Khalid R; Majeed A; Imran I; Saeed H; Usman M; Ali M; Alali AS; AlAsmari AF; Ali N; Asiri AM; Alasmari F; Alqahtani F
Sci Rep; 2021 Apr; 11(1):8589. PubMed ID: 33883647
[TBL] [Abstract][Full Text] [Related]
14. Physiologically based pharmacokinetic modelling and simulation to predict the plasma concentration profile of schaftoside after oral administration of total flavonoids of
Li X; Chen C; Ding N; Zhang T; Zheng P; Yang M
Front Pharmacol; 2022; 13():1073535. PubMed ID: 36588682
[No Abstract] [Full Text] [Related]
15. A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows.
Rasool MF; Khalil F; Läer S
Clin Pharmacokinet; 2015 Sep; 54(9):943-62. PubMed ID: 25773479
[TBL] [Abstract][Full Text] [Related]
16. Physiologically-based pharmacokinetic modeling for single and multiple dosing regimens of ceftriaxone in healthy and chronic kidney disease populations: a tool for model-informed precision dosing.
Alasmari F; Alasmari MS; Muwainea HM; Alomar HA; Alasmari AF; Alsanea S; Alshamsan A; Rasool MF; Alqahtani F
Front Pharmacol; 2023; 14():1200828. PubMed ID: 37547336
[No Abstract] [Full Text] [Related]
17. Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus.
Morita S; Takahashi T; Yoshida Y; Yokota N
Ther Drug Monit; 2016 Apr; 38(2):259-67. PubMed ID: 26587870
[TBL] [Abstract][Full Text] [Related]
18. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Rainsford KD; Parke AL; Clifford-Rashotte M; Kean WF
Inflammopharmacology; 2015 Oct; 23(5):231-69. PubMed ID: 26246395
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis.
Peters SA
Clin Pharmacokinet; 2008; 47(4):261-75. PubMed ID: 18336055
[TBL] [Abstract][Full Text] [Related]
20. A Physiologically Based Pharmacokinetic Model to Predict Systemic Ondansetron Concentration in Liver Cirrhosis Patients.
Alqahtani F; Alruwaili AH; Alasmari MS; Almazroa SA; Alsuhaibani KS; Rasool MF; Alruwaili AF; Alsanea S
Pharmaceuticals (Basel); 2023 Dec; 16(12):. PubMed ID: 38139819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
